Inhibrx Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Inhibrx Biosciences Inc INBX.OQ reported a quarterly adjusted loss of $1.85​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $125.48. The mean expectation of two analysts for the quarter was for a loss of $2.76 per share. Wall Street expected results to range from $-2.92 to $-2.60 per share.

• Revenue rose 1,200% to $1.30 million from a year ago; analysts expected zero.

• Inhibrx Biosciences Inc's reported EPS for the quarter was a loss of $1.85​.

• The company reported a quarterly loss of $28.65 million.

• Inhibrx Biosciences Inc shares had risen by 53.6% this quarter and gained 42.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $12.00, about 82.7% below its last closing price of $21.92

This summary was machine generated from LSEG data August 13 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)